$OKYO News

Last published 6d ago

6d agoOKYOOKYO Pharma to Present at the Stifel 2026 Healthcare ConferenceGlobeNewswireLONDON and NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain
2mo agoOKYOOKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026GlobeNewswireLONDON and NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain
2mo agoOKYOOKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare ConferenceGlobeNewswireLONDON and NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain
3mo agoOKYOOKYO Pharma Announces Purchase of Shares by Chief Scientific OfficerGlobeNewswireLONDON and NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain
3mo agoOKYOOKYO Pharma to Participate in the BTIG Biotechnology Conference 2026GlobeNewswireLONDON and NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain
3mo agoOKYOOKYO Pharma Announces Purchase of Shares by DirectorGlobeNewswireLONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain
3mo agoOKYOOKYO Pharma Announces Purchase of Shares by Chief Executive OfficerGlobeNewswireLONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain
3mo agoOKYOOKYO Pharma Announces Purchase of Shares by Chief Development Officer and DirectorGlobeNewswireLONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain
3mo agoOKYOOKYO Pharma Announces Purchase of Shares by Chief Medical OfficerGlobeNewswireLONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain
3mo agoOKYOOKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual ConferenceGlobeNewswireLONDON and NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain
3mo agoOKYOOKYO Pharma Announces Purchase of Shares by ChairmanGlobeNewswireLONDON and NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain
3mo agoOKYOOKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 PlansGlobeNewswireLONDON and NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain
4mo agoOKYOOKYO Pharma Reports Positive Feedback from FDA Type D Meeting and Accelerates Urcosimod into Global Phase 3 Pivotal Trial for Neuropathic Corneal PainGlobeNewswireFDA alignment on a single-dose Phase 3 study design and potential single-trial registration pathway further strengthens the Company's clinical development program for urcosimodCompany unveils NEPTUNE (Neuropathic
4mo agoOKYOOKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology SymposiumGlobeNewswireLONDON and NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain
5mo agoOKYOOKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhDGlobeNewswireDr. Sacchetti brings international expertise in clinical and translational research on ocular inflammatory and degenerative diseaseOKYO's introduction to the broader ophthalmology community at ASCRS drove strong
6mo agoOKYOOKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in MayGlobeNewswireRobert J. Dempsey, MBA, Chief Executive Officer, to present at EyeceleratorRaj Patil, PhD, Chief Scientific Officer, to present at ARVO LONDON and NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited
7mo agoOKYOOKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual MeetingGlobeNewswireLONDON and NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain
8mo agoOKYOOKYO Abstract Selected for Presentation at Premier Global Ophthalmology CongressGlobeNewswireLONDON and NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain
9mo agoOKYOOKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary SharesGlobeNewswireLONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain
9mo agoOKYOOKYO Pharma Announces Public Offering of Ordinary SharesGlobeNewswireLONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain
9mo agoOKYOOKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink PartnersGlobeNewswireLONDON and NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain
9mo agoOKYOOKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical OfficerGlobeNewswireDr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate®, a blockbuster orphan therapy in corneal diseaseDr. Mantelli will lead the
9mo agoOKYOOKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual MeetingGlobeNewswireLONDON and NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain
9mo agoOKYOOKYO Pharma Announces Successful Type C Meeting with the FDAGlobeNewswireLONDON and NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain
9mo agoOKYOFDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal PainGlobeNewswireLONDON and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain
10mo agoOKYOOKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive OfficerGlobeNewswireAccomplished industry leader Robert J. Dempsey brings extensive commercialization and ophthalmic expertise Gary S. Jacob, Ph.D., will transition to Chief Development Officer and continue to serve on the Board LONDON and
10mo agoOKYOOKYO Pharma to Ring the Opening Bell at NasdaqGlobeNewswireLONDON and NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular
11mo agoOKYOOKYO Pharma Announces Chairman and Founder Acquires SharesGlobeNewswireLONDON and NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an
11mo agoOKYOOKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal PainGlobeNewswirePatients treated with 0.05% urcosimod demonstrated directionally favorable improvements in nerve fiber count and fiber length, trends not observed in the placebo groupThese findings suggest that urcosimod may have a
11mo agoOKYOOKYO Pharma Announces Chairman and Founder Acquires SharesGlobeNewswireLONDON and NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an
11mo agoOKYOOKYO Pharma Announces Chairman and Founder Acquires SharesGlobeNewswireLONDON and NEW YORK, Nov. 21, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an
11mo agoOKYOOKYO Pharma to Present at OIS XV in San DiegoGlobeNewswireLONDON and NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an
1y agoOKYOOKYO Pharma to Present at BIO-Europe 2025 in ViennaGlobeNewswireLONDON and NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a
1y agoOKYOOKYO Pharma Announces Chairman and Founder Acquires SharesGlobeNewswireLONDON and NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an
1y agoOKYOOKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal PainGlobeNewswireLONDON and NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an
1y agoOKYOOKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal PainGlobeNewswireLONDON and NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an
1y agoOKYOOKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal PainGlobeNewswireAfter 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in neuropathic corneal pain (NCP), as measured by Visual Analogue Scale (VAS), demonstrating highly
1y agoOKYOGoldman Small Cap Research Issues New Research Update on OKYO Pharma LimitedACCESS NewswireRaising Price Target Due to Fundamental Drivers BALTIMORE, MD / ACCESS Newswire / June 11, 2025 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced
1y agoOKYOOKYO Pharma to Present at the Bio International ConventionGlobeNewswireLONDON and NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a
1y agoOKYOOKYO Pharma to Present at the GPCRs-Targeted Drug Discovery SummitGlobeNewswireLONDON and NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a
1y agoOKYOFDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal PainGlobeNewswireLONDON and NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod (formerly called OK-101) to treat NCP, an
1y agoOKYOOKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal PainGlobeNewswireUrcosimod phase 2 trial treating Neuropathic Corneal Pain ("NCP") patients was initiated in October 2024 and designed as a double-masked, randomized, 12-week placebo-controlled trial.OKYO Pharma plans to analyze the
1y agoOKYOOKYO Pharma Announces Positive Data in Long-Term Stability of UrcosimodGlobeNewswireUrcosimod in Phase 2 clinical trial for Neuropathic Corneal Pain shown to have Long-Term StabilityUrcosimod stable in single-use ampoules for more than 2½ yearsFDA requires drug to show long-term shelf stability for
1y agoOKYOOKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal PainGlobeNewswireLONDON and NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a
1y agoOKYOOKYO Pharma Announces OK-101 Officially Assigned USAN : UrcosimodGlobeNewswireLONDON and NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP),
1y agoOKYOOKYO Pharma Announces Chairman and CEO Acquire SharesGlobeNewswireLONDON and NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP),
1y agoOKYOGoldman Small Cap Research Publishes New Research Report on OKYO Pharma LimitedACCESS NewswireBALTIMORE, MD / ACCESS Newswire / January 30, 2025 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new research
1y agoOKYOOKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second QuarterGlobeNewswireLONDON and NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP),
1y agoOKYOOKYO Pharma Receives $1.4 Million in Non-Dilutive FundingGlobeNewswireLONDON and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP),
1y agoOKYOOKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology ConferenceGlobeNewswireLONDON and NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP),